sheraton boston hotel and the john b. hynes … · sheraton boston hotel and the john b. hynes...

ISPOR BOSTON

Join colleagues and hear from renowned experts in the HEOR fi eld!ISPOR is recognized globally as the leading scientifi c and educational organization for health economics and outcomes research (HEOR) and its use in health care decisions.

• Learn about different and innovative applications in the conduct and use of HEOR.• Engage with recognized global experts in the fi eld.• Network with colleagues, collaborators, and clients.• Share your research and ideas with other ISPOR members in an open and objective

environment.• Stay current on emerging trends in health care.• Advance your career by being an active participant, i.e., attend an ISPOR Short

Course or network with recognized leaders in HEOR.

Why Attend an ISPOR Meeting?ISPOR meetings provide a forum for discussion and dissemination of HEOR information. These events bring together experts in the fi eld to share innovative research methods and health policy developments and provide an opportunity to network, collaborate, and learn from each other. Held during a time of change, ISPOR Boston will examine drug development, regulatory issues, and decision making through the lens of Evidence and Value in a Time of Social and Policy Change.

Who Attends ISPOR Meetings?The ISPOR scope and sphere of infl uence includes the international HEOR community of global leaders, policy makers, regulators, researchers, academicians, payers, decision makers, patients, and patient groups. This multistakeholder group is invested in using science and research to make better health care decisions.

SHERATON BOSTON HOTEL AND THE JOHN B. HYNES VETERANS MEMORIAL CONVENTION CENTER

ISPOR 22ND ANNUAL INTERNATIONAL MEETINGMAY 20 -24 , 2017 / BOSTON, MA, USA

Evidence and Value in a Time of Social and Policy Change

PROGRAM

Early Registration Deadline: April 11, 2017

#ISPORBostonTrending Topics:• Real-World Evidence • Value Frameworks• Comparative Effectiveness Research • Clinical Outcomes Assessment • Patient Preferences and Engagement • Modeling • Economic Evaluation • Use of Health Policy in Decision Making • Rare Disease • Personalized Medicine • Medical Devices • Oncology • Vaccines • Medication Adherence

Last year’s Annual International Meeting hosted nearly 3,800 attendees from 83 countries and facilitated more than 1,800 presentations!

Program – New Format!You asked. We listened. New scheduling format for ISPOR sessions! In response to feedback from meeting attendees, ISPOR is implementing a new scheduling format for non-plenary sessions. Specific topics of interest (e.g., modeling, PROs, HTA, etc.) will now be available at multiple session times and in a variety of presentation formats (e.g., issue panels, workshops, and podium presentations). The objective is to give attendees the opportunity to concentrate on their preferred areas of interest by offering a greater diversity of topics and presentation types in each session time frame. We hope this new scheduling format better meets your needs so that you get the most out of your ISPOR meeting experience.

ISPOR Boston features more than 1,850 presentations!- Pre-Meeting Short Courses are training courses offered in 7 HEOR topic areas. They range in

skill level from introductory to advanced, and continuing education credits are available. Separate registration is required.

- Plenary Sessions feature thought-provoking presentations on controversial or challenging topics relating to HEOR methodology issues, the application of HEOR in health care decision making, and health policy.

- Issue Panels (IP) introduce debate with multistakeholder perspectives on new or controversial issues in HEOR.

- Workshops (W) discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical, economic, or patient-reported outcomes, patient preferences, and health care policy.

- ISPOR Forums (F) are presented by ISPOR Groups on country/regional health policy, scientific research/initiatives, good practices for outcomes research, research tools, or publications.

- Podium Presentations (P) sessions consist of four 15-minute outcomes research presentations on a single topic (e.g., medication compliance, budget impact, cancer outcomes studies).

- Poster Presentations sessions contain approximately 400 research posters per session arranged by disease, topic, or health care intervention with an hour for author discussion.

- Symposia are sponsored presentations that relate to ISPOR’s mission. The sponsor organization chooses a subject of interest to delegates and arranges suitable speakers.

Networking Connect with ISPOR members, colleagues, collaborators, and clients!- Meet with clients and other attendees. Schedule meetings via the ISPOR Boston mobile app and

web platform (available approximately one month prior to the meeting).

- Let the good times roll! Join your ISPOR colleagues for a night of bowling, billiards, and bites at the ISPOR Social Event on Tuesday evening at Lucky Strike Boston, located steps from Fenway Park. Separate registration required.

- Engage in session discussions with colleagues during the morning and afternoon coffee breaks or during lunch in the Poster and Exhibit Hall.

- Explore the Exhibit Hall and find products and services that meet your needs.

ISPOR Groups Collaborate with members of your ISPOR groups. - ISPOR Regional Groups (Chapters, Networks, and Consortia): Join the educational, research,

and policy-related activities of these groups and meet other HEOR professionals in your region of the world.

- ISPOR Scientific and Health Policy Working Groups (Task Forces, Special Interest Groups, and Council Working Groups): Collaborate with members of these groups and participate in the development of ISPOR knowledge products, such as ISPOR Good Practices for Outcomes Research Reports, manuscripts for Value in Health, and online tools used by decision makers and researchers around the world.

- Students: Network with student members worldwide! Join us at the Student Research Competition, Student and Faculty Icebreaker Reception, Student Research Showcase, Student Forum, and Student Roundtable—all highly attended events! If you are interested in starting a Student Chapter at your University, see http://www.ispor.org/student/howtoform.asp for more information.

page 2 • #ISPORBOSTON

ISPOR would like to thank the current event sponsors of ISPOR Boston:

(Sponsors as of February 2017)

PLATINUM LEVEL: Complete HEOR Solutions (CHEORS), HealthCore Inc., Pharmerit International, and STATinMED Research

GOLD LEVEL: Evidera and Precision for Value

SILVER LEVEL: BaseCase Management GmbH, Boston Health Economics, Genesis Research, and Johnson & Johnson

BRONZE LEVEL: The CPRH™ Exam and ZRx Outcomes Research

Interested in becoming an Event Sponsor? See www.ispor.org/ Event/Sponsorship Opportunities/2017Boston.

Make the most of ISPOR Boston!

First Plenary Session: Where is US Health Policy Going?This plenary session will comprise four leading health economists in the US (two who have advised Democrats and two who have counseled Republicans) to discuss key topical health policy issues facing the US and the world. The panelists will not present slides, but instead will participate in a moderated discussion. After brief opening statements on the economists’ response to “what worries them the most about health policy going forward?,” the discussion will touch upon several key topics: the future of Obamacare and health insurance in the US; drug pricing; health spending trends; and payment and delivery reforms. Moderator: Peter Neumann, ScD, Tufts Medical Center, Boston, MA, USA; Speakers: Jonathan Gruber, PhD, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA; David M. Cutler, PhD, Harvard University, Cambridge, MA, USA; Gail R. Wilensky, PhD, Project HOPE, Bethesda, MD, USA; Joseph R. Antos, PhD, American Enterprise Institute (AEI), Washington, DC, USA

Second Plenary Session: Social Network Interventions and Population Health Human beings choose their friends, and often their neighbors and co-workers, and we inherit our relatives; and each of the people to whom we are connected also does the same, such that, in the end, we humans assemble ourselves into large face-to-face social networks—which we have recently taken online as well. How and why do we do this? And how might an understanding of human social network structure and function be used to intervene in the world? During this session, Dr. Nicholas Christakis will review recent research from his lab describing two classes of interventions—involving both offline and online networks—that can help make the world better: (1) interventions that rewire the connections between people, and (2) interventions that manipulate social contagion. Social contagion interventions modify the flow of desirable or undesirable phenomena between people, ranging from obesity to smoking cessation to altruism to pathogens to medication choice. Dr. Christakis will illustrate what can be done using a variety of experiments in settings as diverse as fostering health behavior change in developing world villages, fostering cooperation in networked groups online, facilitating the diffusion of innovation or coordination in groups, and other examples. By taking account of people’s structural embeddedness in social networks, and by understanding social influence, it is possible to intervene in social systems to enhance desirable population-level properties as diverse as health, wealth, cooperation, coordination, and learning. Moderator: Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA; Speaker: Nicholas A. Christakis, MD, PhD, MPH, Yale University, New Haven, CT, USA

Third Plenary Session: When Do We Really Need Randomized Controlled Trials?Virtually all scientists would agree that, everything else being equal, randomized study designs have stronger internal validity than comparable observational study designs. But does it necessarily follow that results from observational studies are unreliable in guiding treatment decisions and policy choices? This plenary session will address how big data is changing the strength of evidence in observational studies and how this is influencing the types of studies where randomization is necessary. How does the ability to link data from multiple sources (such as medical claims, electronic medical records, sociodemographic data, etc.) affect our confidence in drawing causal inferences from observational data? Does it help to reduce missing variable bias? Or does it introduce bias because the people that link are atypical? What is the evidence that observational studies can replicate the average treatment effects from randomized studies conducted on similar populations to answer similar questions? How do considerations of study cost, speed to answer, feasibility, sample size, and other factors influence study design? This panel of leading researchers and policy experts will provide state-of-the-art viewpoints on the usefulness of big data for health care policy decisions and discuss the challenges remaining. Moderator: William Crown, PhD, OptumLabs, Boston, MA, USA; Speakers: Steven Goodman, MD, MHS, PhD, Stanford University School of Medicine, Stanford, CA, USA; Sebastian Schneeweiss, MD, ScD, Harvard Medical School and Brigham & Women’s Hospital, Boston, MA, USA

MEETING PROGRAM COMMITTEEISPOR thanks the Meeting Program Committee for its contributions in developing the scientific community’s leading HEOR program.

PROGRAM COMMITTEE CO-CHAIRS

William Crown, PhD, OptumLabs, Boston, MA, USA

Peter Neumann, ScD, Tufts Medical Center, Boston, MA, USA

RESEARCH REVIEW COMMITTEE CO-CHAIRS

Rajender R. Aparasu, PhD, University of Houston, Houston, TX, USA

Jan B. Pietzsch, PhD, Wing Tech Inc., Irvine, CA, USA

Laura T. Pizzi, PharmD, MPH, Rutgers University, Piscataway, NJ, USA

Brian Seal, PhD, RPh, MBA, Takeda Pharmaceuticals, Boston, MA, USA

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

Suzanne Belinson, PhD, MPH, Blue Cross Blue Shield Association, Chicago, IL, USA

Newell McElwee, PharmD, MSPH, Merck, Philadelphia, PA, USA

Catherine Tak Piech, PhD, Janssen Scientific Affairs, Titusville, NJ, USA

WORKSHOP REVIEW COMMITTEE CO-CHAIRS

Sachin Kamal-Bahl, PhD, Pfizer, Philadelphia, PA, USA

Nneka Onwudiwe, PharmD, PhD, MBA, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA

David Vanness, PhD, University of Wisconsin, Madison, WI, USA

#ISPORBOSTON • page 3

Plenary Sessions Featured at ISPOR Boston

Economic Methods

• Introduction to Pharmacoeconomics

• Cost-Effectiveness Analysis Alongside Clinical Trials

• Statistical Methods in Economic Evaluations

• Budget Impact Analysis I: A 6-Step Approach

• Budget Impact Analysis II: Applications & Design Issues

Modeling Methods

• Bayesian Analysis—Overview and Applications

• Introduction to Modeling Methods

• Modeling: Design and Structure of a Model

• NEW! Using Dynamic Simulation Models for Decision Making in Health Care Delivery

• Using DICE Simulation for Health Economic Analyses

• Advanced Decision Modeling for Health Economic Evaluations

• Advanced Topics in Decision Analytic Modeling

Observational Data Methods

• Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources

• Applications in Using Large Databases

• Use of Propensity Scores in Observational Studies of Treatment Effects

• Use of Instrumental Variables in Observational Studies of Treatment Effects

• Introduction to Big Data Analysis: Graph Analytics

Outcomes Research Methods

• Meta-Analysis and Systematic Reviews in Comparative-Effectiveness Research

• Network Meta-Analysis

Patient-Preference Methods

• Introduction to Conjoint Analysis

• Utility Measures

• NEW! Collecting Health-State Utility Estimates for Economic Models in Clinical Studies

Patient-Reported Outcomes Methods

• Introduction to Patient-Reported Outcomes

• Advanced Patient-Reported Outcomes

• Patient-Reported Outcomes—Item Response Theory

Use of Pharmacoeconomic/Economic/Outcomes Research Information

• Interoperability and Informatics—Practical Tools and Strategies for Analyzing Real World Data

• Elements of Pharmaceutical/Biotech Pricing I—Introduction

• Case Studies in Pharmaceutical/Biotech Pricing II—Advanced

• Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products

• NEW! US Payers—An Introduction to Their Structures, Evidence Needs, and Decision-Making Process

• Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications

Select courses require the use of your personal laptop.

page 4 • #ISPORBOSTON

The ISPOR Short Course Program, offered in conjunction with ISPOR meetings around the world as a series of 4- and 8-hour training courses, is designed to enhance your knowledge in seven topic areas (“Tracks”) related to health economics and outcomes research. Short courses (many with hands-on training opportunities) range in level from introductory to advanced and are taught by leading experts in the field. Separate Short Course registration is required!

Pre-Meeting Short Course Program

SHORT COURSE FEESALL DAY COURSES

Thru April 11, 2017Standard: $700

Clinical/Government/Academia: $500

Full-Time Students: $150

After April 11, 2017Standard: $800



HALF DAY COURSES

Thru April 11, 2017Standard: $350


Full Time Students: $100

After April 11, 2017Standard: $400



MEETING ENHANCEMENT FEESShort Course Continuing Education Accreditation (CPE & CME): $125

See https://www.ispor.org/Event/ShortCourses/2017Boston for Short Course schedule and descriptions, as well as to register.

Short Courses are offered on Saturday, May 20 and Sunday, May 21 in the following topic areas:

* Program subject to change #ISPORBOSTON • page 5

Meeting Program

SATURDAY, MAY 20

8:00AM-5:00PM SHORT COURSES

5:30PM-6:30PM EDUCATIONAL SYMPOSIUMThe Evolving Approach to Drug Value Assessment in Global Markets (Sponsored by Health Strategies Group)

SUNDAY, MAY 21

8:00AM-5:00PM SHORT COURSES

5:30PM-6:30PM EDUCATIONAL SYMPOSIUMEnabling High-Value Interactions and Value-Based Contracts Between Pharma and Payers Using Claims and EHR Data (Sponsored by Aetion, Inc.)

6:30PM-8:30PM ISPOR STUDENT RESEARCH COMPETITION

6:45PM-7:45PM EDUCATIONAL SYMPOSIUMPrediction and Monitoring of Real-Life Outcomes: The Linchpin in Successful Outcomes-Based Agreements (Sponsored by LASER Analytica)

8:30PM-9:30PM ISPOR STUDENT & FACULTY ADVISOR RECEPTION

MONDAY, MAY 22

6:00AM ISPOR BOSTON 5K RUN

7:15AM-8:15AM EDUCATIONAL SYMPOSIUMHealth Economics and Outcomes Research in the Era of Value-Based Care and the 21st Century Cures Act (Sponsored by Cardinal Health Specialty Solutions)

8:30AM-2:00PM POSTERS – SESSION I

8:30AM-10:30AM WELCOME & FIRST PLENARY SESSIONWhere Is US Health Policy Going?

10:30AM-11:00AM BREAK, EXHIBITS & POSTERS – SESSION I

11:00AM-12:00PM BREAKOUT SESSIONIP1: Future Directions for Cost-Effectiveness AnalysisIP2: Joint ISPOR–ISPE Special Task Force on RWE in Regulatory Decision Making: Will Transparency Improve Acceptability?IP3: Value Assessment Debate: Pluralistic Approach or Does One Size Fit All?W1: Dealing With the Challenges of Providing Information to Payers Prior to Product LaunchP1: Modeling StudiesP2: Pricing and Reimbursement Studies

12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS – SESSION I

12:30PM-1:30PM EDUCATIONAL SYMPOSIUMIs There a Way to Agree on Evidence Requirements Before Evidence Is Generated? (Sponsored by QuintilesIMS)

12:30PM-1:30PM ISPOR STUDENT RESEARCH SHOWCASE

1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR – SESSION I

2:00PM-3:00PM NEW PROFESSIONAL EVENT – CAREER ADVICE ACROSS THE GLOBE

2:15PM-3:15PM BREAKOUT SESSIONIP4: ISPOR’s Special Task Force Report on U.S. Value Assessment Frameworks: What Does It Say and Is It Helpful?

IP5: Voices and Echoes: What Methods Should We Be Using to Capture the Patient Voice?W2: Actuarial and Health Economic Approaches to Assess Value: Speaking the Same Language or Need for Translation?W3: Developing Cost-Effectiveness Models to Assess Value of Immuno-Oncology Therapies: Challenges and ApproachesP3: Infectious and Respiratory Disease StudiesP4: Medicare Studies

3:15PM-3:45PM BREAK & EXHIBITS

3:45PM-4:45PM BREAKOUT SESSIONIP6: Is There Consistency in the Evidence That Payers Report Reviewing When Determining Drug Coverage? Should It Be Consistent?W4: Minding the Gaps: Combining Patient-Centric Valuation, Observational Data Analysis, and Decision Modeling to Deliver Patient-Centered Comparative Effectiveness ResearchW5: ISPOR’s Special Task Force Report on US Value Assessment Frameworks: A Deeper Dive into Its Health Economic UnderpinningsW6: Demystifying Predictive Analytics and an Introduction to Recent Methodological InnovationsP5: Cancer StudiesP6: Cost of Illness and Resource Utilization Studies

3:45PM-7:45PM POSTERS – SESSION II

5:00PM-6:00PM BREAKOUT SESSIONIP7: Controversies in Transparency and Sensitivity Recommendations From the Second Panel on Cost-Effectiveness in Health and MedicineIP8: Performance-Based Risk-Sharing Arrangements: What Are the Latest Views from the Negotiating Table?W7: Are Payers Equipped to Assess the Unique Value of Precision and Personalized Medicine (PPM)? Analyzing Current Value Frameworks and Their Application Within the PPM ContextW8: Good Practices for Synthesizing and Using Evidence in Health Care Decision MakingP7: Personalized Medicine Studies P8: Treatment Patterns Studies

6:00PM-7:45PM EXHIBITORS’ OPEN HOUSE RECEPTION & POSTERS – SESSION II

6:15PM-7:15PM BREAKOUT SESSIONF1: Extending Cost-Effectiveness Analysis With Partial Optimization Modelling and Fiscal Modelling in Vaccine Value AssessmentsF2: How Does Measurement of Multiple Medication Adherence Differ Between Chronic Diseases?F3: New Trends of Health Technology Assessment Development and Value Evidence Requirement for Access and Reimbursement in Asia (China, Japan, South Korea, and Taiwan)F4: Fellowships and Internships: Career Opportunities for the FutureF5: Reimbursement of Oncology Drugs in Arabic CountriesF6: Evolution of the Process of Health Technology Assessment in Mexico: Medical Devices

6:45PM-7:45PM POSTER AUTHOR DISCUSSION HOUR – SESSION II

7:30PM-9:00PM ISPOR GLOBAL NETWORKS RECEPTION

* Program subject to changepage 6 • #ISPORBOSTON

Meeting Program

TUESDAY, MAY 23

7:15AM-8:15AM EDUCATIONAL SYMPOSIUMNew Developments in Psychometric and Utility Methods for Patient-Reported Outcomes Measurement in Health Economic Evaluations (Sponsored by Analysis Group)

8:30AM-2:00PM POSTERS – SESSION III

8:30AM-10:30AM WELCOME & SECOND PLENARY SESSIONSocial Network Interventions and Population Health

10:30AM-11:00AM BREAK, EXHIBITS & POSTERS – SESSION III

11:00AM-12:00PM BREAKOUT SESSIONIP9: Perspectives on the Relationship Between Cost-Effectiveness and AffordabilityIP10: Moving Beyond the QALY in Patient-Centered Value Frameworks: But in What Direction?W9: Report From the ISPOR Value of Information Task ForceW10: Improving Reproducibility and Robustness of Evidence From Large Health Care Databases With Specific Reporting GuidanceP9: Diabetes StudiesP10: Medical Device and Diagnostics Studies

12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS – SESSION III

12:30PM-1:30PM EDUCATIONAL SYMPOSIUMFDAMA 114 and the 21st Century Cures Act: Insights From Payers and Manufacturers, and Implications for the Exchange of Health Care Economic Information (Sponsored by Xcenda)

1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR – SESSION III

1:15PM-2:00PM ISPOR GENERAL BUSINESS MEETING

2:15PM-3:15PM BREAKOUT SESSIONIP11: Making Value Frameworks Fit for Purpose to Guide Decisions – Is There a Need for Empirical Estimates of Opportunity Costs?IP12: Will the 21st Century Cures Act Drive Conduct of Pragmatic Clinical Trials?W11: Stated Preferences in Drug Evaluation: A Comparative Assessment of the Use of Stated Preference in the US, Canada, and the European UnionW12: Opportunities and Challenges in Increasing the Voice of People Affected by Disease in Drug Development, Approvals, and Health Care Technology Assessments: A Case Study in Multiple SclerosisP11: Cost-Effectiveness StudiesP12: Cardiovascular Studies

3:15PM-3:45PM BREAK & EXHIBITS

3:30PM-5:30PM ISPOR STUDENT RESEARCH ADVICE ROUNDTABLE

3:45PM-4:45PM BREAKOUT SESSIONIP13: The Complexities of Medicare Directly Negotiating Drug Prices: What Are the Pros and Cons?IP14: Health Care Economic Information: Considerations for Expanding Proactive Communications by Biopharmaceutical Manufacturers to Population Health Decision MakersW13: ISPOR Clinical Outcome Assessment Measurement in Rare Disease Clinical Trials Emerging Good Practices Task Force – A Case Study on Application of Final Recommendations

W14: Title – TBDP13: Medication Adherence StudiesP14: Patient Preference Studies

3:45PM-7:45PM POSTERS – SESSION IV

5:00PM-6:00PM BREAKOUT SESSIONIP15: Minimal Clinically Important Difference in EQ-5D: We Can Calculate It – But Does That Mean We Should?IP16: FDAMA Section 114 Has Been Replaced by Section 3037 of the Cures Act: Now What?W15: Optimal Allocation of Resources in Managing Medical Device PortfoliosW16: The New Wave in Real World Evidence – Integrated DatasetsP15: Mental Health StudiesP16: Research on Methods Studies

6:00PM-7:45PM EXHIBITORS’ WINE & CHEESE RECEPTION & POSTERS – SESSION IV

6:15PM-7:15PM BREAKOUT SESSIONF7: Performance-Based Risk Sharing Agreements – Opportunities and Challenges for Medical DevicesF8: Challenges in Research and Health Technology Assessment of Rare Disease TechnologiesF9: Health Economic Modeling in OncologyF10: Patient Involvement in Health Technology Assessment in AsiaF11: Solving Health Inequities Across Latin America, Beyond Universal Health CoverageF12: Differential Pricing in Resource-Constrained Environments

6:45PM-7:45PM POSTER AUTHOR DISCUSSION HOUR – SESSION IV

8:00PM-11:30PM ISPOR SOCIAL EVENT

WEDNESDAY, MAY 24

7:30AM-8:30AM EDUCATIONAL SYMPOSIUMValue Is in the Eye of the Beholder: Redefining Market Access Success in a Value-Based Economy (Sponsored by Covance)

8:00AM-1:30PM POSTERS – SESSION V

8:45AM-9:45AM BREAKOUT SESSIONIP17: Cost-Effectiveness Models for Innovative Oncology Treatments: How Different Methodological Approaches Can Be Used to Estimate the Value of Novel Therapies

Meeting Program

* Program subject to change #ISPORBOSTON • page 7

Hotel/Venue Information: The ISPOR 22nd Annual International Meeting will be held at the Sheraton Boston Hotel (39 Dalton Street, Boston, MA, 02199) and John B. Hynes Veterans Memorial Convention Center, located approximately 6 miles (9.5km) from the Boston Logan International Airport and in the heart of the city. Registration and meeting sessions will be held at the Sheraton Boston Hotel. Posters and exhibits will be in the John B. Hynes Veterans Memorial Convention Center (connected to the Sheraton).Discounted room rates are available for ISPOR meeting attendees and reservations can be made online through the Hotel and Venue Information webpage (https://www.ispor.org/Event/EventInformation/2017Boston?p=483). Due to the extensive number of graduations and in-town baseball games, hotel sleeping rooms will be in high demand. Please make your hotel reservation as soon as possible.

Early Registration Deadline: April 11, 2017

MEETING REGISTRATION FEESSTANDARD MEMBER Thru April 11, 2017 Member $825 Non-Member $1,000 After April 11, 2017Member $925 Non-Member $1,100

CLINICAL PRACTITIONERS (CLINICAL PRACTICE, HOSPITAL) Thru April 11, 2017 Member $600 Non-Member $775

After April 11, 2017Member $700 Non-Member $875

FULL-TIME GOVERNMENT AND ACADEMIA Thru April 11, 2017 Member $500 Non-Member $675

After April 11, 2017 Member $600 Non-Member $775

PATIENT REPRESENTATIVE Thru April 11, 2017 Member $175 Non-Member $350


FULL-TIME STUDENTS (must provide current enrollment docs)

Thru April 11, 2017 Member $175 Non-Member $235


ONE DAY REGISTRATION (PER DAY) May 22, May 23, or May 24 Thru April 11, 2017 Member $400 Non-Member $575


MEETING ENHANCEMENT FEESISPOR 5K RUN: Monday, May 22, 5:30AM Member/Non-Member $40

ISPOR SOCIAL EVENT: Tuesday, May 23, 8:00PM-11:30PM Member/Non-Member $75 Student $40

Let the good times roll! Join your ISPOR colleagues for a night of bowling, billiards, and bites at the ISPOR Social Event at Lucky Strike Boston, located steps from Fenway Park.

IP18: Evaluating Gene Therapies: Ready or Not Here They Come IP19: Toward Open Science for Large Health Care Database Research: Improving Reproducibility and Robustness of EvidenceW17: Conducting Qualitative ‘Exit’ Interviews Following Clinical Trials or Observational Studies: A Valuable Method for Understanding the Patient Experience, Informing Measurement Strategy, and Aiding Interpretation of Patient-Reported OutcomesW18: Numbers or Noise? Quantifying the Internal Validity of Stated-Preference DataW19: Can Research and Evaluation Move the Needle on Telehealth and mHealth? Designing, Conducting, and Disseminating Studies That Increase Understanding of Benefits and Incentives

9:45AM-10:15AM BREAK, EXHIBITS & POSTERS – SESSION V

10:15AM-12:00PM WELCOME & THIRD PLENARY SESSIONWhen Do We Really Need Randomized Controlled Trials?

12:00PM-1:45PM LUNCH, EXHIBITS & POSTERS – SESSION V

12:30PM-1:30PM EDUCATIONAL SYMPOSIUMEvidentiary Equilibrium: Balancing Real-World Evidence Development With Stakeholder Requirements (Sponsored by Inventiv Health)

12:30PM-1:30PM POSTER AUTHOR DISCUSSION HOUR – SESSION V

1:45PM-2:45PM BREAKOUT SESSIONIP20: Valuing Precision: How Will Next Generation Diagnostics Change the Landscape for HEOR and Patient Management?IP21: Use of Real-World Evidence to Shape Health Policies for Medical DevicesIP22: Measuring What Matters: Is Standardized Outcomes Measurement Necessary to Support Value-Based Care?W20: Biosimilars in the US – An Opportunity Lost or in the MakingW21: Quantifying Efficiency in Health Care: Time and Motion Methodology to Generate Robust Economic Evidence for Drugs and Medical Devices

2:45PM-3:00PM BREAK

3:00PM-4:00PM BREAKOUT SESSIONIP23: What’s So Unique About the US? A Comparative US-UK Perspective to Debate the Role of US Health System Characteristics in the Development and Implementation of Value FrameworksIP24: Incorporating Patient Preference Information throughout the Medical Product Lifecycle: What Are the Opportunities and Challenges?W22: A Multi-Stakeholder Collaborative Approach to Developing a Patient-Reported Outcome (PRO) Measure for FDA Drug Development Tool Qualification: The PRO Consortium’s Depression Working Group ExperienceW23: Challenges for Implementation of Regulatory HTA in JapanW24: Analysis and Interpretation of Censored Cost Data Using Real-World Evidence: A Step-by-Step Approach

THE “RUN” DOWN:

ISPOR BOSTON 5K RUN

Lace up and start your Monday morning at ISPOR Boston with a run around Castle Island Park!

Race fees benefit the Seema S. Sonnad Ph.D. Memorial Fund for Young Investigators

Includes: Roundtrip transportation to/from the Sheraton Boston Hotel and Castle Island Park and a Race T-Shirt.

Day: MONDAY MORNING, MAY 22, 2017

Time: RACE STARTS AT 6:00AM

Place: CASTLE ISLAND PARK

Race fee: $40

SPONSORED BY:

Race managed by Mike Linnane, Results Event Management

sheraton boston hotel and the john b. hynes … · sheraton boston hotel and the john b. hynes...

Documents